Natural Products (Professional)
Facts & Comparisons > Grapefruit

Grapefruit

Scientific Name(s): Citrus paradisi Macfad. Family: Rutaceae

Common Name(s): Grapefruit

Clinical Overview

Advertisement

Uses of Grapefruit

Grapefruit juice is used as a nutritional supplement to counteract potassium loss. Grapefruit pectin can reduce cholesterol and promote regression of atherosclerosis. Other effects include induction of red cell aggregation by constituent naringin, reduction of hemocrits and possible anti-cancer effects.

Grapefruit Dosing

Grapefruit juice has been given in clinical studies from 1 to 9 glasses daily, or 240 mL of double-strength juice twice daily.

Contraindications

Contraindicated in patients taking medication which is metabolized by liver/cytochrome P450 3A4 (CYP3A4) enzyme system (see Interactions).

Pregnancy/Lactation

Generally recognized as safe or used as food. Safety and efficacy for dosages above those in foods are unproven and should be avoided.

Grapefruit Interactions

Grapefruit juice increases intestinal cell wall metabolism (CYP3A4) of albendazole, amiodarone, benzodiazepines (ie, midazolam and triazolam), buspirone, calcium channel blockers (including amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nisoldipine, and verapamil), carbamazepine, cisapride, clomipramine, cyclosporine, dextromethorphan, estrogens (eg, estrone and ethinyl estradiol), fluvoxamine, HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin but not pravastatin), losartan, macrolide antibiotics (eg, clarithromycin, erythromycin), pimozide, praziquantel, quinidine, saquinavir, and scopolamine. Plasma concentrations of digoxin and sildenafil may be increased; while plasma concentrations of amprenavir, etoposide, fexofenadine, and itraconazole may be decreased. Grapefruit juice appears to delay both the absorption of indinavir and the time to reach peak plasma concentrations of indinavir and quinidine. It would be prudent to advise patients to take these medications with a liquid other than grapefruit juice and to avoid grapefruit juice.

Grapefruit Adverse Reactions

A case report exists about grapefruit juice-induced hypotension.

Toxicology

Grapefruit juice can create adverse effects by altering drugs metabolized by the CYP3A4 enzyme system (eg, some nonsedating antihistamines, benzodiazepines, selected calcium channel blockers, estrogens, quinidine, and cyclosporine).

Botany

The grapefruit is a large, dimpled, round citrus fruit, measuring 3 to 6 inches in diameter. It descends from a cross between a pomelo (pummelo) or shaddock ( C. grandis ), a large Malaysian citrus, and a sweet orange. Others believe the grapefruit may have arisen as a mutation of another type of citrus tree. The fruit grows in clusters similar to grapes, and this may be the reason why the “grapefruit” was so named. The two main varieties of grapefruit include the Duncan (many seeds and good flavor) and the Marsh (seedless with less flavor). The pink varieties followed; the Foster (1907; seeded) and the Thompson (1913; seedless). The Ruby red-pulped grapefruit was developed in the late twenties in McAllen, Texas. Grapefruits can be considered a “New World” product, a species only a few hundred years old. 1 , 2 , 3 The juice of the fruit, including concentrate, accounts for approximately 42% of all US processed grapefruit products. 2

History

In 1310 B.C., Greek historian Theophrastus wrote of how Citron was thought to be an antidote to poison and how it could also “sweeten the breath.” Later, Pliny, a Roman naturalist, used the word “citrus” for the first time and labeled the fruit as a medicine. 4 The grapefruit, then called “small shaddock,” was first mentioned by Griffith Hughes in 1750, as the “forbidden fruit” of Barbados. 1 , 2 The name “grapefruit” was said to have been first used in Jamaica in 1814. In 1823, the grapefruit was introduced in Florida by a French count, Odette Phillippe, but did not begin to gain popularity until the end of the nineteenth century. 1 Worldwide production of grapefruit today averages 4.3 million metric tons. 2

In the 1930's, Hollywood's “Grapefruit Diet” came into vogue, including limitation of calorie intake to approximately 800 per day, and including grapefruit consumption at each meal. Weight can be lost on this diet, but any diet based primarily on one food is too restrictive to be healthy because too many important nutrients may be missing. 5

Analysis of grapefruit seed extract has been performed. 6

Chemistry

The chemistry of citrus fruits has been reviewed. Components of citrus fruits include sugars, polysaccharides, organic acids, nitrogenous constituents, lipids, carotenoids (that contribute to color), vitamins, minerals, flavonoids and volatile components (that contribute to aroma). 7 , 8

Grapefruit is high in water and fiber. 5 The whole fruit is also a good source of potassium, vitamin C, inositol, bioflavonoids and pectin. 2 However, the juice alone is not high in pectin. 4 In addition, grapefruit has no fat and is low in calories and sodium. The pink variety contains beta-carotene. 5 Folic acid is also present in grapefruit. The peel contains citral, an aldehyde that antagonizes the effects of vitamin A. 2

Other constituents in grapefruit have been found to affect liver enzymes. 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, has been identified. 9 Naringin, naringenin, limonin and obacunone also exhibit inhibitory effects in human liver microsomes (see Pharmacology). 10



Grapefruit Uses and Pharmacology

In the US, the grapefruit is popular as a breakfast fruit, usually eaten in halves. Approximately 50% of the world grapefruit crop is made into juice. 2

Nutritional supplement

Nutrition studies have been performed that discovered grapefruit to be of value as a dietary supplement. 11 Grapefruit has also been used as a nutritional supplement for patients experiencing potassium loss. 12

Animal/Clinical data

Research reveals no animal or clinical data regarding the use of grapefruit as a nutritional supplement.

Cholesterol lowering effects

Grapefruit pectin has been found to reduce cholesterol and to promote regression of atherosclerosis. 4 , 13 Because the pectin resides in the cell walls of the fruit and not in the juice, the juice itself does not decrease blood cholesterol. 4

Animal/Clinical data

Research reveals no animal or clinical data regarding the use of grapefruit for cholesterol lowering effects.

Other uses

Other blood effects of grapefruit include induction of red cell aggregation by constituent naringin in vitro and reduction of hematocrits in 36 human subjects who ingested one grapefruit per day. 14

The Swedes have studied grapefruit for its anti-cancer effects. In a 1986 analysis, subjects who consumed citrus fruit daily had lower incidences of pancreatic cancer. 2

A pharmacokinetic study suggests citrus flavanones undergo glucuronidation before urinary excretion. 15

A report discussing treatment of psoriasis with cyclosporine and grapefruit juice is available. 16

Grapefruit juice has been found to increase the bioavailability of certain drugs by inhibition of the cytochrome P450 3A4 (CYP3A4) isozyme found in the liver and gut wall. 17 , 18 , 19 , 20 , 21 The effects of grapefruit juice are primarily on the isozyme found in the gut wall. As a result of this inhibition, more drug is absorbed and the plasma concentration increases. The elevated drug concentration may lead to an increase in the drug's activity and side effects. In some instances, the increase in drug concentration may be beneficial (see Toxicology).

Dosage

Grapefruit juice has been given in clinical studies from 1-9 glasses daily, or 240 mL of double-strength juice twice daily. 22 , 23

Pregnancy/Lactation

Generally recognized as safe or used as food. Safety and efficacy for dosages above those in foods unproven and should be avoided.

Interactions

Grapefruit juice has been reported to interact with numerous drugs. Most studies of grapefruit juice interactions have involved controlled trials in healthy volunteers ingesting the study drug with water and regular- or double-strength grapefruit juice. The mechanism of the majority of these interactions involves inhibition of the cytochrome P450 3A4 (CYP3A4) in the small intestine, which may elevate drug plasma concentrations and increase the risk of side effects. After a 10 oz glass of grapefruit juice the recovery half-life for CYP3A4 activity is approximately 23 hours. 24 Recovery is almost complete within 3 days. In addition, grapefruit juice may decrease or delay drug absorption. In other cases, the mechanism of reported interactions is unknown. Following is a listing of grapefruit-drug interactions categorized on the basis of the best available documentation.

Drug plasma concentrations increased by grapefruit juice, probably due to inhibition of metabolism (CYP3A4) in the small intestine:

Drug plasma concentrations decreased by grapefruit juice, resulting from decreased absorption: Fexofenadine, 86 , 87 , 88 , 89 itraconazole. 90 , 91

Drugs with increased time to reach peak concentrations due to grapefruit juice ingestion: Clarithromycin. 92

Drugs with delayed absorption and time to reach peak concentrations due to grapefruit juice ingestion: Indinavir, 93 , 94 , 95 quinidine. 96 , 97

Drug plasma concentrations slightly increased by grapefruit juice, mechanism unknown: Digoxin, 98 sildenafil. 99 , 100

Drug plasma concentrations decreased by grapefruit juice, mechanism unknown: Amprenavir, 101 etoposide. 102

Drugs that do not appear to interact with grapefruit juice based on available documentation: Alprazolam. 103

Other reports are available regarding the effect of grapefruit juice on caffeine metabolism, 104 inhibition of 11-beta-hydroxysteroid dehydrogenase 105 and shifting the metabolic ratios of clomipramine. 35

Adverse Reactions

Grapefruit juice has been associated with hypotension in one patient. 106

Toxicology

Grapefruit juice can create adverse effects by altering drugs metabolized by the CYP3A4 enzyme system (eg, some nonsedating antihistamines, benzodiazepines, selected calcium channel blockers, estrogens, quinidine, and cyclosporine).

Bibliography

1. Davidson A, et al. Grapefruit, Pomelo, Ugli. Fruit-A Connoiseur's Guide and Cookbook . New York, NY: Simon and Schuster Inc. 1991:66.
2. Ensminger A, et al. Grapefruit Foods and Nutrition Encyclopedia 2nd ed. CRC Press Inc., Boca Raton, FL 1994; 1097-99.
3. Simpson B. et al. Fruits and Nuts of Warm Regions. Economic Botany-Plants in our World . New York, NY: McGraw-Hill Inc. 1995:124.
4. Carper J. Grapefruit. The Food Pharmacy . New York, NY: Bantam Books. 1988:213-15.
5. http://countryliving.com/gh/health/07nutrb3.htm
6. Sakamoto S, et al. Eisei Shikenjo Hokoku 1996;114:38-42.
7. Ranganna S, et al. Crit Rev Food Sci Nutr 1983;18(4):313-86.
8. Ranganna S, et al. Crit Rev Food Sci Nutr 1983;19(1):1-98.
9. Edwards D, et al. Drug Metab Dispos 1996;24(12):1287-90.
10. Fukuda K, et al. Biol Pharm Bull 1997;20(5):560-64.
11. Staroscik J, et al. J Am Diet Assoc 1980;77(5):567-69.
12. Boner G, et al. Harefuah 1980;98(6):251-52.
13. Cerda J. Trans Am Clin Climatol Assoc 1987;99:203-13.
14. Robbins R, et al. Int J Vitam Nutr Res 1988;58(4):414-17.
15. Ameer B, et al. Clin Pharmacol Ther 1996;60(1):34-40.
16. Taniguchi S, et al. Arch Dermatol 1996;132(10):1249.
17. Bailey D, et al. Clin Pharmacokinet 1994;26(2):91-98.
18. Anon. Med Lett Drugs Ther 1995;37(955):73-74.
19. Fuhr U, et al. Clin Pharmacol Ther 1995;58(4):365-73.
20. Spence J. Clin Pharmacol Ther 1997;61(4):395-400.
21. Ameer B, et al. Clin Pharmacokinet 1997;33(2):103-21.
22. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol . 2003 Aug;43(8):831-839.
23. Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet . 2002;41(4):311-318.
24. Greenblatt DJ, et al. Time course of recovery of cytochrome P450 3A function after a single dose of grapefruit juice. Clin Pharmacol Ther . 2003;74:121-129.
25. Nagy J, et al. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg . 2002;66:260-263.
26. Libersa CC, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol . 2000;49:373-378.
27. Josefsson M, et al. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol . 1996;51:189-193.
28. Vincent J, et al. Lack of effect of grapefruit juice on the pharmacokinetics of amlodipine. Br J Clin Pharmacol . 2000;50:455-463.
29. Lilja JJ, et al. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther . 1999;66:118-127.
30. Lilja JJ, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther . 1998;64:655-660.
31. Garg SK, et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther . 1998;64:286-288.
32. Gross AS, et al. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther . 1999;65:395-401.
33. Kivistö KT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther . 1999;66:448-453.
34. Offman EM, et al. Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther . 2001;70:17-23.
35. Oesterheld J, et al. Grapefruit juice and clomipramine: shifting metabolic ratios. J Clin Psychopharmacol . 1997;17:62-63. 36.
36. Lee M, et al. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol . 2001;41:317-323.
37. Ducharme MP, et al. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol . 1993;36:457-459.
38. Herlitz H, et al. Grapefruit juice: a possible source of variability in blood concentration of cyclosporine A. Nephrol Dial Transplant . 1993;8:375.
39. Yee GC, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet . 1995;345:955-956.
40. Hollander AAMJ, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther . 1995;57:318-324.
41. Ducharme MP, et al. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther . 1995;57:485-491.
42. Proppe DG, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol . 1995;39:337.
43. Min DI, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation . 1996;62:123-125.
44. Ioannides-Demos LL, et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol . 1997;24:49-54.
45. Edwards DJ, et al. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther . 1999;65:237-244.
46. Emilia G, et al. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood . 1998;91:362-363.
47. Ku Y-M, et al. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolites in healthy volunteers: does the formulation difference matter? J Clin Pharmacol . 1998;38:959-965.
48. Product information. Cyclosporine ( Neoral ). Novartis Pharmaceutical Corporation. 1999.
49. Di Marco MP, et al. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A4 and P-glycoprotein. Life Sci . 2002;71:1149-1160.
50. Christensen H, et al. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol . 2002;58:515-520.
51. Kanazawa S, et al. The effect of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol . 2001;56:799-803.
52. Schubert W, et al. Inhibition of 17 β-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas . 1994;20:155-163.
53. Weber A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception . 1996;53:41-47.
54. Bailey D, et al. Lancet 1991;337(8736):268-69.
55. Edgar B, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol . 1992;42:313-317.
56. Bailey DG, et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther . 1993;53:637-642
57. Malhotra S, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther . 2001;69:14-23.
58. Dresser GK, et al. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther . 2000;68:28-34.
59. Bailey DG, et al. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther . 2000;68:468-477.
60. Bailey DG, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol . 1995;40:135-140.
61. Bailey DG, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther . 1996;60:25-33.
62. Dresser GK, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P450 3A4 activity in vitro and in vivo. Clin Pharmacol Ther . 2002;72:247-255.
63. Lundahl J, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol . 1995;49:61-67.
64. Hori H, et al. Grapefruit juice-fluvoxamine interaction: is it risky or not? J Clin Psychopharmacol . 2003;23:422-424.
65. Zaidenstein R, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit . 2001;23:369-373.
66. Kantola T, et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther . 1998;63:397-402.
67. Rogers JD, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3methlyglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther . 1999;66:358-366.
68. Anderson V, et al. Intestinal first pass metabolism of midazolam in liver cirrhosis-effect of grapefruit juice. Br J Clin Pharmacol . 2002;54:120-124.
69. Kupferschmidt HHT, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther . 1995; 58:20-28.
70. Uno T, et al. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol . 2000;56:643-649.
71. Azuma J, et al. Effects of grapefruit juice on the pharmacokinetics of the calcium channel blockers nifedipine and nisoldipine. Curr Ther Res . 1998;59:619-634.
72. Takanaga H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther . 2000;67:201-214.
73. Bailey DC, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther . 1993;54:589-594.
74. Product information. Pimozide ( Orap ). Teva Pharmaceuticals. August 1999.
75. Castro N, et al. Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother . 2002;46:1614-1616.
76. Kupferschmidt HHT, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol . 1998;45:355-359.
77. Product information. Saquinavir ( Fortovase ). Roche Laboratories Inc., Nutley, New Jersey. October 2000.
78. Ebert U, et al. Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. Int J Clin Pharmacol Ther . 2000;38:523-531.
79. Lilja JJ, et al. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther . 1998;64:477-483.
80. Lilja JJ, et al. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther . 2000;68:384-390.
81. Vanakoski J, et al. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol . 1996; 50:501-508.
82. Hukkinen SK, et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther . 1995; 58:127-31.
83. Lilja JJ, et al. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol . 2000;56:411-415.
84. Ho PC, et al. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol . 2000;56:693-698.
85. Fuhr U, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol . 2002;58:45-53.
86. Dresser GK, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther . 2002;71:11-20.
87. Kim B, et al. Volume of grapefruit juice and bioavailability of fexofenadine. Clin Pharmacol Ther . 2003;73:48.
88. Dresser GK, et al. Duration of grapefruit juice effect on fexofenadine interaction. Clin Pharmacol Ther . 2003:73:P48.
89. Penzak SR, et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit . 1999;21:304-309.
90. Kawakami M, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Clin Pharmacol Ther .1998;36:306-309.
91. Fuhr U, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther . 1998;36:136-132.
92. Cheng KL, et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother . 1998;42:927-929.
93. Shelton MJ, et al. Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol . 2001;41:435-442.
94. Product information. Indinavir ( Crixivan ). Merck & Co., Inc. February 2001.
95. Penzak SR, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol . 2002;42:1165-1170.
96. Min DI, et al. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol . 1996;36:469-476.
97. Ho PC, et al. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol . 1999;55:393-398.
98. Becquemont L, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther . 2001;70:311-316.
99. Jetter A, et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther . 2002;71:21-29.
100. Lee M, et al. Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. Ther Drug Monit . 2001;23:21-26.
101. Demarles D, et al. Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice. Antimicrob Agents Chemother . 2002;46:1589-1590.
102. Reif S, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol . 2002;58:491-494.
103. Yasui N, et a. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology . 2000;150:185-190.
104. Fuhr U, et al. Int J Clin Pharmacol Ther 1995;33(6):311-14.
105. Lee Y, et al. Clin Pharmacol Ther 1996;59(1):62-71.
106. Nilsson I. Lakartidningen 1997;94(3):112-13.
107. Yee G, et al. Lancet 1995;345(8955):955-56.
108. Miniscalco A, et al. J Pharmacol Exp Ther 1992;261(3):1195-99.
109. Lundahl J, et al. Eur J Clin Pharmacol 1997;52(2):139-45.
110. Sigusch H, et al. Pharmazie 1994;49(9):675-79.
111. Benton R, et al. Clin Pharmacol Ther 1996;59(4):383-88.
112. Honig P, et al. J Clin Pharmacol 1996;36(4):345-51.
113. Clifford C, et al. Eur J Clin Pharmacol 1997;52(4):311-15.
114. Rau S, et al. Clin Pharmacol Ther 1997;61(4):401-09.
115. Bennett W. Pediatr Nephrol 1995;9(1):10.
116. Majeed A, et al. Pediatr Nephrol 1996;10(3):395-96.
117. Vanakowski J, et al. Eur J Clin Pharmacol 1996;50(6):501-08.
118. Pisarik P. Arch Fam Med 1996;5(7):413-16.
119. Rashid T, et al. Br J Clin Pharmacol 1995;40(1):51-58.

 

User reviews

0 review(s) for Grapefruit


MedNotes
Advertisement

(web3)